Pharmamarketeer

ViiV’s two-drug regimen gets EU approval for HIV-1

ViiV Healthcare has announced that its HIV therapy Juluca (dolutegravir/rilpivirine) has been awarded marketing authorisation in the EU from the European Commission, making it the first available two-drug regimen, daily single pill solution for the type 1 of the virus (HIV-1).

 

Reageer

Medhc-fases-banner
Advertentie(s)